Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker SPRY
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 25,000 | $10.00 | $250.0K Sale | Form 4 ↗ |
| Jun 12, 2026 | Alexander A. Fitzpatrick Chief Legal Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 3,355 | $10.00 | $33.5K Sale | Form 4 ↗ |
| Nov 13, 2025 | Brian Dorsey Chief Operating Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 21,828 | $8.71 | $190.1K Sale | Form 4 ↗ |
| Nov 12, 2025 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 136,380 | $8.86 | $1.2M Sale | Form 4 ↗ |
| Nov 12, 2025 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 30,000 | $8.91 | $267.3K Sale | Form 4 ↗ |
| Aug 21, 2025 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $14.49 | $724.5K Sale | Form 4 ↗ |
| Aug 21, 2025 | Kathleen D. Scott Chief Financial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 12,500 | $15.00 | $187.5K Sale | Form 4 ↗ |
| Aug 20, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 37,656 | $14.09 | $530.6K Sale | Form 4 ↗ |
| Aug 19, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 12,344 | $14.03 | $173.2K Sale | Form 4 ↗ |
| Jul 1, 2025 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 15,000 | $16.99 | $254.8K Sale | Form 4 ↗ |
| Jun 27, 2025 | James E. Flynn 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 370,074 | $18.46 | $6.8M Sale | Form 4 ↗ |
| Jun 27, 2025 | James E. Flynn 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 370,075 | $18.46 | $6.8M Sale | Form 4 ↗ |
| Jun 18, 2025 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 15,000 | $16.00 | $240.0K Sale | Form 4 ↗ |
| May 20, 2025 | Alexander A. Fitzpatrick Chief Legal Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 102,969 | $14.10 | $1.5M Sale | Form 4 ↗ |
| May 20, 2025 | Brent L. Saunders Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 120,000 | $14.25 | $1.7M Sale | Form 4 ↗ |
| May 20, 2025 | Kathleen D. Scott Chief Financial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $14.10 | $705.0K Sale | Form 4 ↗ |
| Apr 7, 2025 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,002 | $12.30 | $615.0K Sale | Form 4 ↗ |
| Mar 20, 2025 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 10,000 | $14.00 | $140.0K Sale | Form 4 ↗ |
| Mar 6, 2025 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 49,600 | $11.21 | $556.0K Sale | Form 4 ↗ |
| Mar 5, 2025 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 400 | $11.00 | $4,400 Sale | Form 4 ↗ |
| Feb 3, 2025 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $12.31 | $615.5K Sale | Form 4 ↗ |
| Jan 6, 2025 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $11.10 | $555.0K Sale | Form 4 ↗ |
| Dec 17, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $11.67 | $583.5K Sale | Form 4 ↗ |
| Dec 17, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $11.67 | $583.5K Sale | Form 4 ↗ |
| Dec 17, 2024 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $11.67 | $583.5K Sale | Form 4 ↗ |
| Dec 17, 2024 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $11.67 | $583.5K Sale | Form 4 ↗ |
| Dec 13, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 27,272 | $12.06 | $328.9K Sale | Form 4 ↗ |
| Dec 12, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 117,333 | $12.27 | $1.4M Sale | Form 4 ↗ |
| Dec 12, 2024 | Brian Dorsey Chief Operating Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 25,000 | $12.30 | $307.5K Sale | Form 4 ↗ |
| Dec 11, 2024 | Brian Dorsey Chief Operating Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 15,000 | $12.43 | $186.4K Sale | Form 4 ↗ |
| Dec 10, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.15 | $657.5K Sale | Form 4 ↗ |
| Dec 10, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.16 | $658.0K Sale | Form 4 ↗ |
| Dec 10, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.17 | $658.5K Sale | Form 4 ↗ |
| Dec 10, 2024 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.16 | $658.0K Sale | Form 4 ↗ |
| Dec 10, 2024 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.17 | $658.5K Sale | Form 4 ↗ |
| Dec 6, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $14.23 | $711.5K Sale | Form 4 ↗ |
| Dec 5, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 49,640 | $14.13 | $701.4K Sale | Form 4 ↗ |
| Dec 4, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 45,000 | $13.95 | $627.8K Sale | Form 4 ↗ |
| Dec 4, 2024 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 14,772 | $13.75 | $203.1K Sale | Form 4 ↗ |
| Dec 4, 2024 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 6,283 | $14.00 | $88.0K Sale | Form 4 ↗ |
| Dec 3, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 45,000 | $13.19 | $593.5K Sale | Form 4 ↗ |
| Dec 3, 2024 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 87,984 | $13.26 | $1.2M Sale | Form 4 ↗ |
| Dec 2, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 45,000 | $13.67 | $615.1K Sale | Form 4 ↗ |
| Dec 2, 2024 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 901 | $14.34 | $12.9K Sale | Form 4 ↗ |
| Dec 2, 2024 | Laura Shawver Director | SPRY ARS Pharmaceuticals, Inc. | Sale | 96,343 | $13.55 | $1.3M Sale | Form 4 ↗ |
| Dec 2, 2024 | Eric Karas Chief Commercial Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 3,717 | $14.11 | $52.4K Sale | Form 4 ↗ |
| Nov 27, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 25,000 | $14.39 | $359.8K Sale | Form 4 ↗ |
| Nov 26, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 42,186 | $14.05 | $592.7K Sale | Form 4 ↗ |
| Nov 25, 2024 | Justin Chakma Chief Business Officer | SPRY ARS Pharmaceuticals, Inc. | Sale | 32,814 | $14.00 | $459.4K Sale | Form 4 ↗ |
| Nov 19, 2024 | Richard E. Lowenthal PRESIDENT AND CEO, Director, 10% owner | SPRY ARS Pharmaceuticals, Inc. | Sale | 50,000 | $13.95 | $697.5K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances